NMNAT2 Functional Landscape and Localization in Programmed Axon Degeneration
The Neuroscientist · 2026-12 · 32 (6) · 491-499
DOI: 10.1177/10738584261476959 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The Neuroscientist, online erschienen am 25.08.2026. Verfasst von Alan Nicol und 4 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, Melbourne, Australia. Hauptthemen laut MEDLINE: Nicotinamide-Nucleotide Adenylyltransferase, Axons, Armadillo Domain Proteins, Cytoskeletal Proteins. Die Arbeit nennt 54 Literaturangaben. Gefördert von: Vetenskapsrådet, European Research Council, The BrightFocus Foundation.
Abstract (Originalsprache)
Why is NMNAT2 (and the NAD-NMNAT2-SARM1 axis) important? Axon loss is a common and early driver of disability across neurodegenerative diseases, peripheral neuropathies, traumatic injury, and neurotoxic chemotherapy. A major conceptual advance from the Wallerian degeneration research field is that axons can execute an intrinsic self-destruction program (programmed axon degeneration) that is actively suppressed in healthy axons. NMNAT2 acts as the central endogenous axon maintenance factor in this system: it is highly labile; it must be continuously delivered from the soma into axons; and when its levels fall, axon degeneration is triggered through activation of SARM1, an NAD-consuming enzyme. This makes NMNAT2 a mechanistically grounded therapeutic node: stabilizing it, improving axonal delivery, or blocking downstream SARM1 can strongly preserve axons in diverse injury and disease contexts. NMNAT2 is a short-lived axonal NAD biosynthetic enzyme that maintains a low NMN:NAD ratio to restrain the executioner SARM1, thereby preserving axon integrity. This review integrates NMNAT2’s localization-dependent pools, turnover mechanisms, upstream stressors, downstream SARM1 signaling, and engineered and disease-associated variants. A localization-aware representation of NMNAT2’s functions, trafficking, proteostatic regulation, upstream stressors, and genetic variants should enable targeted experimental design and therapeutic hypothesis generation aimed at stabilizing axons. Here the functional landscape and localization of NMNAT2 in neurodegeneration is examined, ending with gaps identified in the literature and strategies to address these.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, Melbourne, Australia.
- Ophthalmology, Department of Surgery, University of Melbourne, Melbourne, Australia.
- Division of Eye and Vision, Department of Clinical Neuroscience, St Erik Eye Hospital, Karolinska Institutet, Stockholm, Sweden.
- Department of Organic Chemistry, University of Chemistry and Technology in Prague, Prague, Czech Republic.
ORCID-Profile: Flora Hui, Pete A Williams
Förderung
- Vetenskapsrådet
- European Research Council
- The BrightFocus Foundation
- The Ulla and Ingemar Dahlberg Foundation
- Centre for Eye Research Australia philanthropic funds
Zitieren
APA
Nicol, A., Hopkins, E., Hui, F., Brancale, A., & Williams, P. A. (2026). NMNAT2 Functional Landscape and Localization in Programmed Axon Degeneration. The Neuroscientist, 32(6), 491-499. https://doi.org/10.1177/10738584261476959
Vancouver
Nicol A, Hopkins E, Hui F, Brancale A, Williams PA. NMNAT2 Functional Landscape and Localization in Programmed Axon Degeneration. The Neuroscientist. 2026;32(6):491-499. doi:10.1177/10738584261476959
BibTeX
@article{Nicol2026,
author = {Nicol, Alan and Hopkins, Eleanor and Hui, Flora and Brancale, Andrea and Williams, Pete A},
title = {NMNAT2 Functional Landscape and Localization in Programmed Axon Degeneration},
journal = {The Neuroscientist},
year = {2026},
volume = {32},
number = {6},
pages = {491--499},
doi = {10.1177/10738584261476959}
}
EUVIMED